GRTS - GRITSTONE BIO INC. (NASDAQ: GRTS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Gritstone bio Inc. | Benzinga
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
- Do you, or did you, own shares of Gritstone bio, Inc. (NASDAQ:GRTS)?
- Did you purchase your shares between March 9, 2023 and February 29, 2024, inclusive?
- Did you lose money in your investment in Gritstone bio, Inc.?
- Do you want to discuss your rights?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ:GRTS) between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
If you purchased or acquired Gritstone securities, and/or would like to discuss your legal rights and options please visit Gritstone bio, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
Gritstone is a clinical-stage biotechnology company that engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. In September 2023, Gritstone entered into a contract with the Biomedical Advanced Research and Development Authority ("BARDA") to run a 10,000 ...
GRTS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Gritstone bio, Inc.>Full story available on Benzinga.com